chartexchange

Pasithea Therapeutics (KTTA) Reports Promising Phase 1/1b Trial Data for Neurofibromatosis Treatment

GuruFocus | Nov 13, 2026 5:50 AM EST

Related Stocks: KTTA ,

Read original article